Jumpcode Genomics Names Brandon Poe Chief Financial Officer
Seasoned finance and life sciences executive, Brandon Poe, joins rapidly growing team, supporting company growth
SAN DIEGO, CA – Jumpcode Genomics, a genome technology platform company focused on improving the understanding of human biology, announced today that Brandon Poe has joined as Chief Financial Officer. Poe brings 25 years of financial experience in the life sciences, medical devices, and genomics services industries. He will be responsible for overseeing all aspects of finance, operations, and strategic initiatives to support Jumpcode’s continued momentum.
“Brandon has the ideal experience that we were looking for. He has led companies through pivotal stages of growth, acquisitions, and other milestones across a variety of sectors of the life sciences and healthcare industries,” said Yaron Hakak, Ph.D., CEO of Jumpcode Genomics. “We’re about to enter a key period in our evolution and growth, and Brandon’s strategic insights will be integral to our continued success. We are delighted to welcome him to the Jumpcode team.”
Brandon most recently served as CFO at Genome Medical, a genomic telehealth provider, where he led all aspects of finance. Prior to that, he was Vice President of Finance at Illumina, and has held senior finance positions at other companies including Sotera Wireless and Inverness Medical Innovations. He received a bachelor’s degree from Bucknell University and an MBA from the University of Chicago Booth School of Business.
“Jumpcode Genomics is at an important point in its history. As a commercial-stage company with truly enabling technology and deep relationships with academic, life sciences, and biopharmaceutical organizations, Jumpcode has a tremendous opportunity to empower innovation and fuel discovery in science and medicine,” said Poe. “It’s an exciting time to join the team and I’m looking forward to helping guide the company through the next phase of growth.”
About Jumpcode Genomics
Jumpcode Genomics is changing the way scientists see their samples with our CRISPRclean® technology. Combining CRISPR-based technology and next-generation sequencing (NGS) they can now search for and find novel signals they previously couldn’t. Our technology removes unwanted sequences, allowing researchers worldwide to extract greater insights. By increasing sensitivity and allowing access to a range of sample types, we’re broadening the understanding of human biology in fields from research to clinical applications including infectious disease and oncology.
Discover what we can do.